Retroviral oncogenes: A historical primer

Nature Reviews Cancer

Volumn 12, Issue 9, 2012, Pages 639-648

  Vogt, Peter K ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MOS PROTEIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR B; PROTEIN C JUN; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAS PROTEIN; UNCLASSIFIED DRUG; VIRUS RNA;

HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS; REVIEW; ROUS SARCOMA ONCOVIRUS; TUMOR VIRUS; VIRUS GENOME; VIRUS REPLICATION;

CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; HISTORY, 20TH CENTURY; HUMANS; MEDICAL ONCOLOGY; MOLECULAR BIOLOGY; RETROVIRIDAE;

EID: 84866347303     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3320     Document Type: Review

References (197)

1. Temin, H. M. & Rubin, H. Characteristics of an assay for Rous sarcoma virus and Rous sarcoma cells in tissue culture. Virology 6, 669-688 (1958).
2. Hanafusa, H., Hanafusa, T. & Rubin, H. Analysis of the defectiveness of Rous sarcoma virus. I. Characterization of the helper virus. Virology 22, 591-601 (1964).
3. Hanafusa, H., Hanafusa, T. & Rubin, H. Analysis of the defectiveness of Rous sarcoma virus, II. Specification of RSV antigenicity by helper virus. Proc. Natl Acad. Sci. USA 51, 41-48 (1964).
4. Rubin, H. & Vogt, P. K. An avian leukosis virus associated with stocks of Rous sarcoma virus. Virology 17, 184-194 (1962).
5. Martin, G. S. The road to Src. Oncogene 23, 7910-7917 (2004).
6. Temin, H. M. The control of cellular morphology in embryonic cells infected with rous sarcoma virus in vitro. Virology 10, 182-197 (1960).
7. Yoshii, S. & Vogt, P. K. A mutant of rous sarcoma virus (type O) causing fusiform cell transformation. Proc. Soc. Exp. Biol. Med. 135, 297-301 (1970).
8. Hanafusa, H., Hanafusa, T. & Rubin, H. The defectiveness of Rous sarcoma virus. Proc. Natl Acad. Sci. USA 49, 572-580 (1963).
9. Temin, H. M. Separation of morphological conversion and virus production in Rous sarcoma virus infection. Cold Spring Harb. Symp. Quant. Biol. 27, 407-414 (1962).
10. Goldé, A. & Lacassagne, M. Non-défectivité de la souche de virus de Rouse de Schmidt-Ruppin. C. R. Acad. Sci. Hebd. Seances Acad. Sci. D. 262, 329-331 (1966) (in French).
11. Duff, R. G. & Vogt, P. K. Characteristics of two new avian tumor virus subgroups. Virology 39, 18-30 (1969).
12. Martin, G. S. & Duesberg, P. H. The a subunit in the RNA of transforming avian tumor viruses. I. Occurrence in different virus strains. II. Spontaneous loss resulting in nontransforming variants. Virology 47, 494-497 (1972).
13. Vogt, P. K. Spontaneous segregation of nontransforming viruses from cloned sarcoma viruses. Virology 46, 939-946 (1971).
14. Martin, G. S. Rous sarcoma virus: a function required for the maintenance of the transformed state. Nature 227, 1021-1023 (1970).
15. Toyoshima, K. & Vogt, P. K. Temperature sensitive mutants of an avian sarcoma virus. Virology 39, 930-931 (1969).
16. Duesberg, P. H. & Vogt, P. K. Differences between the ribonucleic acids of transforming and nontransforming avian tumor viruses. Proc. Natl Acad. Sci. USA 67, 1673-1680 (1970).
17. Bernstein, A., MacCormick, R. & Martin, G. S. Transformation- defective mutants of avian sarcoma viruses: the genetic relationship between conditional and nonconditional mutants. Virology 70, 206-209 (1976).
18. Wang, L. H., Duesberg, P. H., Kawai, S. & Hanafusa, H. Location of envelope-specific and sarcoma-specific oligonucleotides on RNA of Schmidt-Ruppin Rous sarcoma virus. Proc. Natl Acad. Sci. USA 73, 447-451 (1976).
19. Baltimore, D. RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature 226, 1209-1211 (1970).
20. Temin, H. M. & Mizutani, S. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 226, 1211-1213 (1970).
21. Stehelin, D., Varmus, H. E., Bishop, J. M. & Vogt, P. K. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260, 170-173 (1976).
22. Roussel, M. et al. Three new types of viral oncogene of cellular origin specific for haematopoietic cell transformation. Nature 281, 452-455 (1979).
23. Coffin, J. Hughes, S. & Varmus, H. (eds) Retroviruses (Cold Spring Harbor Laboratory Press, 1997).
24. Strauss, J. & Strauss, E. Viruses and Human Disease (Academic Press, 2007).
25. Flint, S., Enquist, L. & Racaniello, V. Principles of Virology (ASM Press, 2009).
26. Temin, H. Nature of the provirus of Rous sarcoma. Natl Cancer Inst. Monogr. 17, 557-570 (1964).
27. Temin, H. M. The participation of DNA in Rous sarcoma virus production. Virology 23, 486-494 (1964).
28. Vogt, P. & Bader, A. in Encyclopedia of Virology (eds Mahy, B. W. J. & van Regenmortel, M. H. V.) 445-450 (Elsevier, 2008).
29. Varmus, H. E. Form and function of retroviral proviruses. Science 216, 812-820 (1982).
30. Brugge, J. S. & Erikson, R. L. Identification of a transformation-specific antigen induced by an avian sarcoma virus. Nature 269, 346-348 (1977).
31. Collett, M. S. & Erikson, R. L. Protein kinase activity associated with the avian sarcoma virus src gene product. Proc. Natl Acad. Sci. USA 75, 2021-2024 (1978).
32. Levinson, A. D., Oppermann, H., Levintow, L., Varmus, H. E. & Bishop, J. M. Evidence that the transforming gene of avian sarcoma virus encodes a protein kinase associated with a phosphoprotein. Cell 15, 561-572 (1978).
33. Hunter, T. & Sefton, B. M. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc. Natl Acad. Sci. USA 77, 1311-1315 (1980).
34. Ushiro, H. & Cohen, S. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J. Biol. Chem. 255, 8363-8365 (1980).
35. Hunter, T. Tyrosine phosphorylation: thirty years and counting. Curr. Opin. Cell Biol. 21, 140-146 (2009).
36. Czernilofsky, A. P. et al. Corrections to the nucleotide sequence of the src gene of Rous sarcoma virus. Nature 301, 736-738 (1983).
37. Czernilofsky, A. P. et al. Nucleotide sequence of an avian sarcoma virus oncogene (src) and proposed amino acid sequence for gene product. Nature 287, 198-203 (1980).
38. Schwartz, D. E., Tizard, R. & Gilbert, W. Nucleotide sequence of Rous sarcoma virus. Cell 32, 853-869 (1983).
39. Takeya, T., Feldman, R. A. & Hanafusa, H. DNA sequence of the viral and cellular src gene of chickens. 1. Complete nucleotide sequence of an EcoRI fragment of recovered avian sarcoma virus which codes for gp37 and pp60src. J. Virol. 44, 1-11 (1982).
40. Coussens, P. M., Cooper, J. A., Hunter, T. & Shalloway, D. Restriction of the in vitro and in vivo tyrosine protein kinase activities of pp60c-src relative to pp60v-src. Mol. Cell. Biol. 5, 2753-2763 (1985).
41. Iba, H., Cross, F. R., Garber, E. A. & Hanafusa, H. Low level of cellular protein phosphorylation by nontransforming overproduced p60c-src. Mol. Cell. Biol. 5, 1058-1066 (1985).
42. Iba, H., Takeya, T., Cross, F. R., Hanafusa, T. & Hanafusa, H. Rous sarcoma virus variants that carry the cellular src gene instead of the viral src gene cannot transform chicken embryo fibroblasts. Proc. Natl Acad. Sci. USA 81, 4424-4428 (1984).
43. Sadowski, I., Stone, J. C. & Pawson, T. A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. Mol. Cell. Biol. 6, 4396-4408 (1986).
44. Pawson, T. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 116, 191-203 (2004).
45. Sicheri, F., Moarefi, I. & Kuriyan, J. Crystal structure of the Src family tyrosine kinase Hck. Nature 385, 602-609 (1997).
46. Xu, W., Doshi, A., Lei, M., Eck, M. J. & Harrison, S. C. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell 3, 629-638 (1999).
47. Martin, G. S. The hunting of the Src. Nature Rev. Mol. Cell Biol. 2, 467-475 (2001).
48. Duesberg, P. H., Bister, K. & Vogt, P. K. The RNA of avian acute leukemia virus MC29. Proc. Natl Acad. Sci. USA 74, 4320-4324 (1977).
49. Bister, K., Ramsay, G., Hayman, M. J. & Duesberg, P. H. OK10, an avian acute leukemia virus of the MC 29 subgroup with a unique genetic structure. Proc. Natl Acad. Sci. USA 77, 7142-7146 (1980).
50. Duesberg, P. H. & Vogt, P. K. Avian acute leukemia viruses MC29 and MH2 share specific RNA sequences: evidence for a second class of transforming genes. Proc. Natl Acad. Sci. USA 76, 1633-1637 (1979).
51. Kan, N. C., Flordellis, C. S., Garon, C. F., Duesberg, P. H. & Papas, T. S. Avian carcinoma virus MH2 contains a transformation-specific sequence, mht, and shares the myc sequence with MC29, CMII, and OK10 viruses. Proc. Natl Acad. Sci. USA 80, 6566-6570 (1983).
52. Bister, K., Hayman, M. J. & Vogt, P. K. Defectiveness of avian myelocytomatosis virus MC29: isolation of long-term nonproducer cultures and analysis of virus-specific polypeptide synthesis. Virology 82, 431-448 (1977).
53. Maxam, A. M. & Gilbert, W. A new method for sequencing DNA. Proc. Natl Acad. Sci. USA 74, 560-564 (1977).
54. Sanger, F. & Coulson, A. R. A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J. Mol. Biol. 94, 441-448 (1975).
55. Dalla-Favera, R. et al. Cloning and characterization of different human sequences related to the onc gene (v-myc) of avian myelocytomatosis virus (MC29). Proc. Natl Acad. Sci. USA 79, 6497-6501 (1982).
56. Alitalo, K. et al. Nucleotide sequence to the v-myc oncogene of avian retrovirus MC29. Proc. Natl Acad. Sci. USA 80, 100-104 (1983).
57. Abrams, H. D., Rohrschneider, L. R. & Eisenman, R. N. Nuclear location of the putative transforming protein of avian myelocytomatosis virus. Cell 29, 427-439 (1982).
58. Blackwood, E. M. & Eisenman, R. N. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251, 1211-1217 (1991).
59. Eisenman, R. N. The Max network: coordinated transcriptional regulation of cell growth and proliferation. Harvey Lect. 96, 1-32 (2000).
60. Seitz, V. et al. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma. PLoS ONE 6, e26837 (2011).
61. Ikegaki, N., Minna, J. & Kennett, R. H. The human L-myc gene is expressed as two forms of protein in small cell lung carcinoma cell lines: detection by monoclonal antibodies specific to two myc homology box sequences. EMBO J. 8, 1793-1799 (1989).
62. Schwab, M. et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305, 245-248 (1983).
63. Depinho, R. A. et al. Myc family genes: a dispersed multi-gene family. Ann. Clin. Res. 18, 284-289 (1986).
64. Dalla-Favera, R. et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl Acad. Sci. USA 79, 7824-7827 (1982).
65. Schwab, M. et al. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc. Natl Acad. Sci. USA 81, 4940-4944 (1984).
66. Liu, P. et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nature Med. 17, 1116-1120 (2011).
67. Soucek, L. et al. Modelling Myc inhibition as a cancer therapy. Nature 455, 679-683 (2008).
68. Harvey, J. J. An unidentified virus which causes the rapid production of tumours in mice. Nature 204, 1104-1105 (1964).
69. Kirsten, W. H. & Mayer, L. A. Morphologic responses to a murine erythroblastosis virus. J. Natl Cancer Inst. 39, 311-335 (1967).
70. Shih, T. Y., Weeks, M. O., Young, H. A. & Scolnick, E. M. Identification of a sarcoma virus-coded phosphoprotein in nonproducer cells transformed by Kirsten or Harvey murine sarcoma virus. Virology 96, 64-79 (1979).
71. Parks, W. P. & Scolnick, E. M. In vitro translation of Harvey murine sarcoma virus RNA. J. Virol. 22, 711-719 (1977).
72. Hager, G. L. et al. Molecular cloning of the Harvey sarcoma virus closed circular DNA intermediates: initial structural and biological characterization. J. Virol. 31, 795-809 (1979).
73. Tsuchida, N., Ryder, T. & Ohtsubo, E. Nucleotide sequence of the oncogene encoding the p21 transforming protein of Kirsten murine sarcoma virus. Science 217, 937-939 (1982).
74. Tsuchida, N. & Uesugi, S. Structure and functions of the Kirsten murine sarcoma virus genome: molecular cloning of biologically active Kirsten murine sarcoma virus DNA. J. Virol. 38, 720-727 (1981).
75. Gibbs, J. B., Sigal, I. S., Poe, M. & Scolnick, E. M. Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc. Natl Acad. Sci. USA 81, 5704-5708 (1984).
76. McGrath, J. P., Capon, D. J., Goeddel, D. V. & Levinson, A. D. Comparative biochemical properties of normal and activated human ras p21 protein. Nature 310, 644-649 (1984).
77. Scolnick, E. M., Papageorge, A. G. & Shih, T. Y. Guanine nucleotide-binding activity as an assay for src protein of rat-derived murine sarcoma viruses. Proc. Natl Acad. Sci. USA 76, 5355-5359 (1979).
78. Sweet, R. W. et al. The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature 311, 273-275 (1984).
79. Kamata, T. & Feramisco, J. R. Epidermal growth factor stimulates guanine nucleotide binding activity and phosphorylation of ras oncogene proteins. Nature 310, 147-150 (1984).
80. Downward, J., Riehl, R., Wu, L. & Weinberg, R. A. Identification of a nucleotide exchange-promoting activity for p21ras. Proc. Natl Acad. Sci. USA 87, 5998-6002 (1990).
81. Wolfman, A. & Macara, I. G. A cytosolic protein catalyzes the release of GDP from p21ras. Science 248, 67-69 (1990).
82. McCormick, F. Signal transduction. How receptors turn Ras on. Nature 363, 15-16 (1993).
83. Kan, N. C., Flordellis, C. S., Mark, G. E., Duesberg, P. H. & Papas, T. S. A common onc gene sequence transduced by avian carcinoma virus MH2 and by murine sarcoma virus 3611. Science 223, 813-816 (1984).
84. Rapp, U. R. & Todaro, G. J. Generation of oncogenic mouse type C viruses: in vitro selection of carcinoma-inducing variants. Proc. Natl Acad. Sci. USA 77, 624-628 (1980).
85. Jansen, H. W. et al. Homologous cell-derived oncogenes in avian carcinoma virus MH2 and murine sarcoma virus 3611. Nature 307, 281-284 (1984).
86. Jansen, H. W., Ruckert, B., Lurz, R. & Bister, K. Two unrelated cell-derived sequences in the genome of avian leukemia and carcinoma inducing retrovirus MH2. EMBO J. 2, 1969-1975 (1983).
87. Moodie, S. A., Willumsen, B. M., Weber, M. J. & Wolfman, A. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 260, 1658-1661 (1993).
88. Vojtek, A. B., Hollenberg, S. M. & Cooper, J. A. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74, 205-214 (1993).
89. Warne, P. H., Viciana, P. R. & Downward, J. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 364, 352-355 (1993).
90. Rodriguez-Viciana, P. et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370, 527-532 (1994).
91. Adari, H., Lowy, D. R., Willumsen, B. M., Der, C. J. & McCormick, F. Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science 240, 518-521 (1988).
92. Scheffzek, K. et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277, 333-338 (1997).
93. Reddy, E. P., Reynolds, R. K., Santos, E. & Barbacid, M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300, 149-152 (1982).
94. Tabin, C. J. et al. Mechanism of activation of a human oncogene. Nature 300, 143-149 (1982).
95. Taparowsky, E. et al. Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature 300, 762-765 (1982).
96. Trahey, M. & McCormick, F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238, 542-545 (1987).
97. Willingham, M. C., Pastan, I., Shih, T. Y. & Scolnick, E. M. Localization of the src gene product of the Harvey strain of MSV to plasma membrane of transformed cells by electron microscopic immunocytochemistry. Cell 19, 1005-1014 (1980).
98. Finegold, A. A., Schafer, W. R., Rine, J., Whiteway, M. & Tamanoi, F. Common modifications of trimeric G proteins and ras protein: involvement of polyisoprenylation. Science 249, 165-169 (1990).
99. Schafer, W. R. et al. Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 245, 379-385 (1989).
100. Perucho, M. et al. Human-tumor-derived cell lines contain common and different transforming genes. Cell 27, 467-476 (1981).
101. Shih, C., Padhy, L. C., Murray, M. & Weinberg, R. A. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290, 261-264 (1981).
102. Der, C. J., Krontiris, T. G. & Cooper, G. M. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc. Natl Acad. Sci. USA 79, 3637-3640 (1982).
103. Parada, L. F., Tabin, C. J., Shih, C. & Weinberg, R. A. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297, 474-478 (1982).
104. Santos, E. et al. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 223, 661-664 (1984).
105. Malumbres, M. & Barbacid, M. RAS oncogenes: the first 30 years. Nature Rev. Cancer 3, 459-465 (2003).
106. Hall, A., Marshall, C. J., Spurr, N. K. & Weiss, R. A. Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature 303, 396-400 (1983).
107. Engelbreth-Holm, J. & Rothe Meyer, A. On the connection between erythroblastosis (H?ocytoblastosis), myelosis and sarcoma in chicken. APMIS 12, 352-365 (1935).
108. Bister, K. & Jansen, H. W. Oncogenes in retroviruses and cells: biochemistry and molecular genetics. Adv. Cancer Res. 47, 99-188 (1986).
109. Bister, K. & Duesberg, P. H. Structure and specific sequences of avian erythroblastosis virus RNA: evidence for multiple classes of transforming genes among avian tumor viruses. Proc. Natl Acad. Sci. USA 76, 5023-5027 (1979).
110. Lai, M. M., Hu, S. S. & Vogt, P. K. Avian erythroblastosis virus: transformation-specific sequences form a contiguous segment of 3.25 kb located in the middle of the 6-kb genome. Virology 97, 366-377 (1979).
111. Hihara, H., Yamamoto, H., Shimohira, H., Arai, K. & Shimizu, T. Avian erythroblastosis virus isolated from chick erythroblastosis induced by lymphatic leukemia virus subgroup A. J. Natl Cancer Inst. 70, 891-897 (1983).
112. Boerner, J. L., Danielsen, A. & Maihle, N. J. Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm. Exp. Cell Res. 284, 111-121 (2003).
113. Vennstrom, B., Fanshier, L., Moscovici, C. & Bishop, J. M. Molecular cloning of the avian erythroblastosis virus genome and recovery of oncogenic virus by transfection of chicken cells. J. Virol. 36, 575-585 (1980).
114. Yamamoto, T., Hihara, H., Nishida, T., Kawai, S. & Toyoshima, K. A new avian erythroblastosis virus, AEV-H, carries erbB gene responsible for the induction of both erythroblastosis and sarcomas. Cell 34, 225-232 (1983).
115. Yamamoto, T. et al. The erbB gene of avian erythroblastosis virus is a member of the src gene family. Cell 35, 71-78 (1983).
116. Nishida, T. et al. Comparison of genome structures among three different strains of avian erythroblastosis virus. Gann 75, 325-333 (1984).
117. Hayman, M. J., Royer-Pokora, B. & Graf, T. Defectiveness of avian erythroblastosis virus: synthesis of a 75K gag-related protein. Virology 92, 31-45 (1979).
118. Rettenmier, C. W. Anderson, S.M., Riemen, M.W. & Hanafusa, H. gag-Related polypeptides encoded by replication-defective avian oncoviruses. J. Virol. 32, 749-761 (1979).
119. Hayman, M. J. et al. Identification and characterization of the avian erythroblastosis virus erbB gene product as a membrane glycoprotein. Cell 32, 579-588 (1983).
120. Privalsky, M. L., Sealy, L., Bishop, J. M., McGrath, J. P. & Levinson, A. D. The product of the avian erythroblastosis virus erbB locus is a glycoprotein. Cell 32, 1257-1267 (1983).
121. Hayman, M. J. & Beug, H. Identification of a form of the avian erythroblastosis virus erb-B gene product at the cell surface. Nature 309, 460-462 (1984).
122. Privalsky, M. L. & Bishop, J. M. Subcellular localization of the v-erb-B protein, the product of a transforming gene of avian erythroblastosis virus. Virology 135, 356-368 (1984).
123. Privalsky, M. L., Ralston, R. & Bishop, J. M. The membrane glycoprotein encoded by the retroviral oncogene v-erb-B is structurally related to tyrosine-specific protein kinases. Proc. Natl Acad. Sci. USA 81, 704-707 (1984).
124. Kris, R. M. et al. Antibodies against a synthetic peptide as a probe for the kinase activity of the avian EGF receptor and v-erbB protein. Cell 40, 619-625 (1985).
125. Decker, S. J. Phosphorylation of the erbB gene product from an avian erythroblastosis virus-transformed chick fibroblast cell line. J. Biol. Chem. 260, 2003-2006 (1985).
126. Downward, J. et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307, 521-527 (1984).
127. Ullrich, A. et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309, 418-425 (1984).
128. Hatanpaa, K. J., Burma, S., Zhao, D. & Habib, A. A. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 12, 675-684 (2010).
129. Mellinghoff, I. K. et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024 (2005).
130. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
131. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
132. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306-13311 (2004).
133. Yamamoto, H., Toyooka, S. & Mitsudomi, T. Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 63, 315-321 (2009).
134. Plowman, G. D. et al. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl Acad. Sci. USA 90, 1746-1750 (1993).
135. Plowman, G. D. et al. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc. Natl Acad. Sci. USA 87, 4905-4909 (1990).
136. Schechter, A. L. et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229, 976-978 (1985).
137. Bargmann, C. I., Hung, M. C. & Weinberg, R. A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45, 649-657 (1986).
138. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987).
139. Cobleigh, M. A. et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648 (1999).
140. Amin, D. N., Campbell, M. R. & Moasser, M. M. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin. Cell Dev. Biol. 21, 944-950 (2010).
141. Muraoka-Cook, R. S., Feng, S. M., Strunk, K. E. & Earp, H. S. ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition. J. Mammary Gland Biol. Neoplasia 13, 235-246 (2008).
142. Kung, H. J., Boerkoel, C. & Carter, T. H. Retroviral mutagenesis of cellular oncogenes: a review with insights into the mechanisms of insertional activation. Curr. Top. Microbiol. Immunol. 171, 1-25 (1991).
143. Maki, Y., Bos, T. J., Davis, C., Starbuck, M. & Vogt, P. K. Avian sarcoma virus 17 carries the jun oncogene. Proc. Natl Acad. Sci. USA 84, 2848-2852 (1987).
144. Li, J. & Vogt, P. K. The retroviral oncogene qin belongs to the transcription factor family that includes the homeotic gene fork head. Proc. Natl Acad. Sci. USA 90, 4490-4494 (1993).
145. Chang, H. W. et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 276, 1848-1850 (1997).
146. Curran, T. & Teich, N. M. Candidate product of the FBJ murine osteosarcoma virus oncogene: characterization of a 55,000-dalton phosphoprotein. J. Virol. 42, 114-122 (1982).
147. Vogt, P. K. The story of Jun. Arch. Biochem. Biophys. 316, 1-4 (1995).
148. Vogt, P. K. Jun, the oncoprotein. Oncogene 20, 2365-2377 (2001).
149. Li, Z., Tuteja, G., Schug, J. & Kaestner, K. H. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell 148, 72-83 (2012).
150. Myatt, S. S. & Lam, E. W. The emerging roles of forkhead box (Fox) proteins in cancer. Nature Rev. Cancer 7, 847-859 (2007).
151. Schaffhausen, B. S. & Roberts, T. M. Lessons from polyoma middle T antigen on signaling and transformation: A DNA tumor virus contribution to the war on cancer. Virology 384, 304-316 (2009).
152. Whitman, M., Kaplan, D. R., Schaffhausen, B., Cantley, L. & Roberts, T. M. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 315, 239-242 (1985).
153. Cantley, L. C. et al. Oncogenes and phosphatidylinositol turnover. Ann. NY Acad. Sci. 488, 481-490 (1986).
154. Kaplan, D. R. et al. Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity. Cell 50, 1021-1029 (1987).
155. Courtneidge, S. A. & Heber, A. An 81 kd protein complexed with middle T antigen and pp60c-src: a possible phosphatidylinositol kinase. Cell 50, 1031-1037 (1987).
156. Whitman, M., Downes, C. P., Keeler, M., Keller, T. & Cantley, L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 332, 644-646 (1988).
157. Yuan, T. L. & Cantley, L. C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497-5510 (2008).
158. Engelman, J. A., Luo, J. & Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Rev. Genet. 7, 606-619 (2006).
159. Aoki, M. et al. The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity. J. Biol. Chem. 275, 6267-6275 (2000).
160. Sun, M., Hart, J. R., Hillmann, P., Gymnopoulos, M. & Vogt, P. K. Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase. Cell Cycle 10, 3731-3739 (2011).
161. Chaussade, C., Cho, K., Mawson, C., Rewcastle, G. W. & Shepherd, P. R. Functional differences between two classes of oncogenic mutation in the PIK3CA gene. Biochem. Biophys. Res. Commun. 381, 577-581 (2009).
162. Zhao, L. & Vogt, P. K. Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl Acad. Sci. USA 105, 2652-2657 (2008).
163. Miled, N. et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317, 239-242 (2007).
164. Shekar, S. C. et al. Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J. Biol. Chem. 280, 27850-27855 (2005).
165. Georgescu, M. M. PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer 1, 1170-1177 (2010).
166. Courtney, K. D., Corcoran, R. B. & Engelman, J. A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28, 1075-1083 (2010).
167. Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y. & Mills, G. B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Rev. Drug Discov. 4, 988-1004 (2005).
168. Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
169. Maehama, T. & Dixon, J. E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273, 13375-13378 (1998).
170. Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947 (1997).
171. Feldman, M. E. & Shokat, K. M. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs). Curr. Top. Microbiol. Immunol. 347, 241-262 (2010).
172. Sherr, C. J. Principles of tumor suppression. Cell 116, 235-246 (2004).
173. Lovat, F., Valeri, N. & Croce, C. M. MicroRNAs in the pathogenesis of cancer. Semin. Oncol. 38, 724-733 (2011).
174. Morris, K. V. & Vogt, P. K. Long antisense non-coding RNAs and their role in transcription and oncogenesis. Cell Cycle 9, 2544-2547 (2010).
175. Druker, B. J. Translation of the Philadelphia chromosome into therapy for CML. Blood 112, 4808-4817 (2008).
176. Corcoran, R. B., Settleman, J. & Engelman, J. A. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2, 336-346 (2011).
177. Engelman, J. A. & Janne, P. A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 14, 2895-2899 (2008).
178. Hayward, W. S., Neel, B. G. & Astrin, S. M. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 290, 475-480 (1981).
179. Kool, J. & Berns, A. High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. Nature Rev. Cancer 9, 389-399 (2009).
180. Berk, A. J. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 24, 7673-7685 (2005).
181. Munger, K. et al. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78, 11451-11460 (2004).
182. Bracken, A. P., Ciro, M., Cocito, A. & Helin, K. E2F target genes: unraveling the biology. Trends Biochem. Sci. 29, 409-417 (2004).
183. Sullivan, C. S. & Pipas, J. M. T antigens of simian virus 40: molecular chaperones for viral replication and tumorigenesis. Microbiol. Mol. Biol. Rev. 66, 179-202 (2002).
184. Massague, J. G1 cell-cycle control and cancer. Nature 432, 298-306 (2004).
185. Damania, B. Oncogenic γ-herpesviruses: comparison of viral proteins involved in tumorigenesis. Nature Rev. Microbiol. 2, 656-668 (2004).
186. Hecht, J. L. & Aster, J. C. Molecular biology of Burkitt's lymphoma. J. Clin. Oncol. 18, 3707-3721 (2000).
187. Smith, S. M., Anastasi, J., Cohen, K. S. & Godley, L. A. The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. Blood Cells Mol. Dis. 45, 317-323 (2010).
188. Klapproth, K. & Wirth, T. Advances in the understanding of MYC-induced lymphomagenesis. Br. J. Haematol. 149, 484-497 (2010).
189. Corvi, R., Savelyeva, L. & Schwab, M. Patterns of oncogene activation in human neuroblastoma cells. J. Neurooncol 31, 25-31 (1997).
190. Taylor, M. D. et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 123, 465-472 (2012).
191. Swartling, F. J. Myc proteins in brain tumor development and maintenance. Ups. J. Med. Sci. 117, 122-131 (2012).
192. Scheurlen, W. G. et al. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J. Clin. Oncol. 16, 2478-2485 (1998).
193. Huang, P. H., Xu, A. M. & White, F. M. Oncogenic EGFR signaling networks in glioma. Sci. Signal. 2, re6 (2009).
194. Zavoral, M., Minarikova, P., Zavada, F., Salek, C. & Minarik, M. Molecular biology of pancreatic cancer. World J. Gastroenterol. 17, 2897-2908 (2011).
195. Morris, J. P.t., Wang, S. C. & Hebrok, M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nature Rev. Cancer 10, 683-695 (2010).
196. Perez-Mancera, P. A. & Tuveson, D. A. Physiological analysis of oncogenic K-ras. Methods Enzymol. 407, 676-690 (2006).
197. Poulikakos, P. I. & Rosen, N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 19, 11-15 (2011).